Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 73% of modeled bridge. Strengths: Occupancy Rate, Bed Count. Risk-adjusted uplift: $1.3M (vs $1.7M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $660K | $660K | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $635K | $18K | $653K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $101K | $300K | $402K | $1.3M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $21K | $21K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 52.2% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $165K | $330K | $495K | $660K | $660K | $660K | $660K |
| Denial Rate Reduction | $0 | $163K | $327K | $490K | $653K | $653K | $653K | $653K |
| A/R Days Reduction | $0 | $134K | $268K | $402K | $402K | $402K | $402K | $402K |
| Clean Claim Rate | $0 | $11K | $21K | $21K | $21K | $21K | $21K | $21K |
| Cumulative | $0 | $473K | $945K | $1.4M | $1.7M | $1.7M | $1.7M | $1.7M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $1.7M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 50% / 7.6x | 54% / 8.8x | 58% / 10.0x | 60% / 10.6x | 62% / 11.2x |
| 9.0x | 45% / 6.4x | 49% / 7.4x | 53% / 8.5x | 55% / 9.0x | 57% / 9.6x |
| 10.0x | 40% / 5.4x | 45% / 6.4x | 49% / 7.3x | 51% / 7.8x | 53% / 8.3x |
| 11.0x | 36% / 4.6x | 41% / 5.5x | 45% / 6.4x | 47% / 6.8x | 49% / 7.2x |
| 12.0x | 32% / 4.0x | 37% / 4.8x | 41% / 5.6x | 43% / 6.0x | 45% / 6.4x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 1% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 6.4x, adding 2.0 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $5.4M | — | $5.4M | 16.5% |
| Year 1 | $5.6M | +$1.2M | $6.8M | 20.5% |
| Year 2 | $5.8M | +$1.7M | $7.5M | 22.8% |
| Year 3 | $5.9M | +$1.7M | $7.7M | 23.3% |
| Year 4 | $6.1M | +$1.7M | $7.9M | 23.8% |
| Year 5 | $6.3M | +$1.7M | $8.0M | 24.4% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $330K | $495K | $660K | $792K |
| Denial Rate Reductio | $327K | $490K | $653K | $784K |
| A/R Days Reduction | $201K | $301K | $402K | $482K |
| Clean Claim Rate | $11K | $16K | $21K | $25K |
| Total | $868K | $1.3M | $1.7M | $2.1M |
Peer Context — Where This Hospital Sits
Key metrics vs 80 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 16.5% | -27.2% | -16.8% | -1.4% | P96 |
| Net-to-Gross | 18.6% | 20.3% | 41.1% | 52.2% | P19 |
| Occupancy | 75.8% | 14.7% | 25.6% | 49.9% | P92 |
| Rev/Bed | $1.4M | $338K | $604K | $1.0M | P85 |
| Exp/Bed | $1.2M | $484K | $731K | $1.4M | P68 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.